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Abstract
Background: The study was aimed at determining the prevalence of secondary amyloidosis in a
group of Iranian patients with Rheumatoid Arthritis (RA), and the assessment of its correlation with
the clinical and laboratory findings and data.
Method: A total number of 220 patients (167 female and 53 male) with a minimum five-year
history of RA were selected. Congo red staining method was used for staining the specimens
obtained by abdominal subcutaneous fat biopsy (ASFB) method. All of the specimens were
examined for apple-green birefringence under polarized light microscope. Clinical and laboratory
characteristics of the patients were assessed. Chi-square test and unpaired student's t-test were
run for intergroup comparisons.
Results:  Amyloid deposition test yielded positive results in 15 out of the 220 cases (6.8%)
examined by the ASFB technique. Thirteen patients were found to have minimal amyloid deposits.
Of all the clinically significant cases, 8 (53%) presented with proteinuria, and 7 cases (46.6%) had
severe constipation.
Conclusion: The prevalence of fat amyloid deposits in Iranian patients with RA is low. In up to half
of the study group the deposits were subclinical. Follow up studies are required to determine
whether this subclinical amyloidosis can develop into full-blown clinically significant amyloidosis.
Background
Reactive or secondary amyloidosis is a well-known signif-
icant late complication of chronic inflammatory disease,
especially rheumatoid arthritis (RA) [1].
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In this condition, large amounts of amyloid molecules (of
the AA type) are deposited over a wide area. The main
clinical manifestations of secondary amyloidosis (SA) are
marked proteinuria and gastrointestinal symptoms. Gen-
erally, the disease carries a poor prognosis, and causes
death in 2–9% of the cases [2,3].
The prevalence of SA in RA patients in western countries
varies between 8 and 54%, according to the ethnicity of
the subject, the method of amyloid detection, and other
variables in the patients' condition [4].
The simplest most reliable method for amyloid deposi-
tion screening, which is considered gold standard proce-
dure, is abdominal subcutaneous fat aspiration (ASFA)
method. Congo red staining is used in the procedure [5].
The abdominal fat pad aspiration method has a sensitivity
of 26.5 and 82% for the detection of amyloid deposits in
RA cases and in sure amyloidosis cases respectively [6-9].
Another method, that is other than the ASFA method,
namely the biopsy technique, has been given clinical trial
to develop a more sensitive method for detecting amyloid
deposits [10-12]. Barile et al showed that tru cut needle
biopsy has a sensitivity of 78% for amyloid detection. The
study did not show any correlation between amyloid dep-
osition and the clinical manifestations of the disease [10].
Breedveld obtained 54% positive results using the biopsy
method rather than the aspiration method in a diverse
inflammatory arthritic group, and with samples taken
from different sites[11].
In the two studies mentioned, the selected subjects were
too diverse in their clinical picture and/or too few for any
definitive conclusion to be drawn from the test results that
were obtained. It would therefore be quite reasonable to
conclude that the biopsy method affords greater sensitiv-
ity to amyloid deposition; therefore, it yields more accu-
rate results compared with the aspiration method in the
detection of amyloid deposits.
A variety of studies have been conducted to determine the
prevalence of secondary amyloidosis in RA patients; they
have yielded varying results in accordance with the type of
geographic population studied and the diagnostic
method used [12]. The data, published as case series or
case reports, show that the prevalence of secondary amy-
loidosis in the Middle Eastern region, and in the neigh-
boring countries of Iran, is low [13,14]. Our study, which
to the best of our knowledge is the first of its kind, was
directly aimed at investigating the prevalence of amyloid
deposition in Iranian patients using fat-pad biopsy
method; it also sought to establish whether and how its
occurrence correlated with the clinical and laboratory
findings and data respectively.
Methods
Participants
The subjects were selected from a pool of patients referred
to two out-patient clinics of Rasool Akram and Baqiyatol-
lah hospitals in Tehran, Iran, within the period of Decem-
ber 2001 through October 2003.
Inclusions
All of the subjects fulfilled the 1987 American College of
Rheumatology (ACR) classification criteria for RA [15].
They were included in the study consecutively. The dura-
tion of the disease for all the subjects was longer than 5
years, and their disease was still active. All the patients had
been referred to the aforementioned clinics by specialists.
Exclusions
Patients with an onset of disease earlier than 16 years of
age, coexisting chronic disease itself capable of inducing
amyloidosis (e.g. chronic infection), and those otherwise
declining to take part in the trial were excluded from the
study.
All of the 220 patients that took part in the study gave
their written informed consent prior to entering the study.
The approval of the Ethics Committee of the Research
Department of the University was sought and obtained.
Method
Small samples (minimum size 3*3 mm) of abdominal fat
pad were obtained through a small periumbilical incision,
under local induced anesthesia by 1 ml lidocaine 1%. The
specimens were fixed in 10% formalin. On the same occa-
sion, an 18 gauge needle connected to a 10 ml syringe was
inserted into the periumblical fat tissue. A suction force
was applied to aspirate fat samples, which were subse-
quently mounted on 3 microscope slides, and left to air-
dry prior to being fixed in 10% formalin solution as fixa-
tive. The entire procedure on all the subjects was per-
formed by the same doctor. The samples were
subsequently stained with Congo red stain and examined
under polarized light microscope. Two independent
pathologists blindly examined the specimens.
The intensity of the staining was assessed by visual estima-
tion in all the 3 samples for each patient. The amounts of
amyloid deposits found were rated as: negative for no
detectable amyloid deposits in a small isolated area, mild
(+) for little, less than 10 % involvement, moderate (++)
for amyloid deposition between 10 and 60 % involve-
ment, and severe (+++) for involvement of over 60% of
the test area. Where any conflict occurred between the
examiners' test results, the smallest value was considered.
Patient variables, including age, disease duration, age at
the onset of the disease, presence or absence of constipa-BMC Musculoskeletal Disorders 2006, 7:43 http://www.biomedcentral.com/1471-2474/7/43
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tion, and the use of disease-modifying anti-rheumatic
drugs (DMARDs), such as gold and D-penicillamine, were
noted and duly taken into account. Muscle strength was
measured by 5 degree force score normally applied during
routine physical examination [16]. Functional disability
status was evaluated by revised criteria for the classifica-
tion of global functional status [17]. Radiographic dam-
age was evaluated according to the Steinbrocker criteria
for the classification of the progression of rheumatoid
arthritis. Thorough physical examination was conducted
and complete blood count, ESR, IgM rheumatoid factor,
and C reactive protein values were obtained and duly
taken into account. Urinalysis results and 24-hour urine
protein values, where indicated, were also obtained. Plain
hand X-rays were obtained for all the patients.
Statistical analysis was performed with spss version ll.5.
The chi-squared test and unpaired student t-test were run
for intergroup comparisons. A p value of less than 0.05
was considered significant. RA patients with proteinuria
and positive results for amyloid deposition, using the
ASFB method, were diagnosed with clinical amyloidosis.
Results
Fat tissue specimens were obtained from all the 220
patients. Amyloid deposition test result was found posi-
tive in 15 of the 220 cases. Thirteen of the specimens
showed minimal (+) amyloid deposition, with 2 speci-
mens showing moderate (++) amyloid deposition, but
none with severe (+++) amyloid deposition.
Ten out of the 15 cases that tested positive for amyloid
deposition by biopsy method also tested positive for it by
fat aspiration method. Nine out of the 15 (60%) cases had
clinical amyloidosis, and presented with marked pro-
teinuria of between 300 mg to 800 mg in 24-hour urine
collection (P < 0.05). None of the patients had developed
pedal edema, and none was taking gold or D-penicilla-
mine therapy. Proteinuria was also present in 17 out of
205 patients (8%) who tested negative for amyloidosis
with the ASFB method. In these patients the intensity of
proteinuria was less than 500 mg/24 h. After one year's
follow-up study none of the asymptomatic cases were
found to have developed any renal abnormalities. Consti-
pation was present more frequently in the patients who
tested positive for amyloid deposition (P < 0.05).
No significant difference was found related to such varia-
bles as age, sex, or duration of the disease between the
patients who tested positive for amyloid deposition and
those who tested negative (Table 1).
A greater number of the patients who tested positive for
amyloid deposition presented with higher functional dis-
ability class than the ones that tested negative for amyloid
deposition (P < 0.05). No significant difference in labora-
tory findings was found between the patients that tested
positive for amyloid deposition and the ones that tested
negative for it, as shown in Table 1.
Discussion
Secondary amyloidosis is a well-known complication of
RA. The prevalence of secondary amyloidosis in rheuma-
toid arthritis patients varies considerably according to the
geographical population studied and the diagnostic
method used.
The prevalence of amyloidosis in Western countries varies
greatly from region to region [7,10,18]. Recent studies
using ASFA method in detecting amyloidosis in Asian and
North African countries have also yielded varying results.
Wakhlu et al showed in a study that 30 out of 113
Table 1: Comparison of clinical and laboratory variables of amyloid positive and negative patients with rhumatoid arthritis.
Amyloid positive Amyloid Negative P* value
- Total patient, no (%) 15(6.8) 205(93.2) -
- Age, yrs, mean ± SD 55.2 ± 12(32–75) 51.6 ± 13.2 (22–80) NS
- Male: Female, no 3:12 50: 155 NS
- Age at disease onset yrs. Mean ± SD 46.07 ± 7.33 (27–65) 40.18 ± 6.39 (17–70) NS
- Disease duration, yrs, Mean ± SD 9.13 ± 4.67 (5–20) 11.41 ± 6.85 (5–39) NS
- Constipation no (%) 7(46.6) 39(19) <0.019
- Proteinuria, no. (%) 9(60) 17(8.3) <0.001
- RF. Positive, no. (%) 10(66) 130(63.7) NS
- CRP, *No, (%) 13(86) 156(67) NS
- Receiving DMARD, no, (%) 12(80) 155(75.6) NS
- Past use of gold, no (%) 0 17(8.3) NS
Functional class Class 3 No (%) 7 49 < 0.5
Class 4 No (%) 2 4
RF: Rheumatoid Factor; CRP: C-reactive protein; DMARD: Disease Modifying Antirheumatic Drug.
*Normal value <2.3 mg/l.BMC Musculoskeletal Disorders 2006, 7:43 http://www.biomedcentral.com/1471-2474/7/43
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(26.5%) adult Asian RA patients from northern India
tested positive for amyloid deposition by the ASFA
method [9]. Mansouri et al detected amyloid deposits in
8 out of 112 (7%) of the smears taken from Egyptian RA
patients using the ASFA method [8] (Table 2).
The prevalence of secondary amyloidosis in the Middle
Eastern region and the neighboring countries of Iran has
not been established with certainty.
Published data are available as case series or case reports.
Ozdogan et al published the case reports of 147 Turkish
patients with juvenile chronic arthritis compiled retro-
spectively [13]. A 10% incidence of secondary amyloido-
sis was found in the study group. Only a single case of
juvenile chronic arthritis and amyloid deposition was
reported in a Saudi patient [14].
It seems that the biopsy method yields more positive
results than those obtained using the aspiration method.
Barile performed an ASFB with a tru-cut needle in 50 Mex-
ican RA patients in order to investigate the presence of sec-
ondary amyloidosis in them. Amyloid deposits were
found in 78% of the cases, but no correlation was estab-
lished between amyloid deposition and the clinical man-
ifestations of disease [10]. The largest series of studies was
that conducted by Kobayashi et al on a group of Japanese
patients [12]. Of the 407 cases studied, 54 (13.3%) were
found to have gastrointestinal amyloidosis on gastroduo-
denal endoscopy.
In our study, a group of consecutive RA patients were
examined for evaluation using the SAFB method. A preva-
lence of 6.8% in amyloid deposition was found in the 220
cases studied with a mean disease duration of 9 years. It is
a lower incidence than that obtained in the Mexican and
Japanese series using the biopsy method. This disparity
can be attributed to a lower prevalence of secondary amy-
loidosis in the specific geographic population studied.
In a Spanish survey of 313 RA patients with a history of
the disease longer than five years, amyloid deposition was
detected in 16% of the cases, using the ASFA test [7]. Com-
mon clinical features of nephropathy were present in 25%
of these amyloid-positive cases. In asymptomatic amy-
loid-positive patients, long-term follow-up did not show
any overt amyloidosis in the majority of the cases. This
was found to be the case not only at the time of perform-
ing the ASFA test, but also after a long follow-up period.
In our study, 60% of amyloid-positive cases presented
with clinical proteinuria. None of the 220 patients studied
presented with nephrotic or malabsorption syndromes.
Although a statistical difference was found in the severity
of the proteinuria (up to 800 mg/24 h) between amyloid-
positive and amyloid-negative groups as shown in Table
2, its clinical significance cannot be confirmed at this
stage.
A correlation was suggested between the presence of clin-
ical amyloidosis and the intensity of amyloid deposition.
Kobayashi et al found that the clinical manifestations sug-
gestive of systemic amyloidosis in gastroduodenal
mucosa were more frequent in the group with marked
amyloid deposition than in the group that presented with
mild amyloid deposition. (47% vs 14%, P < 0.05) [12].
Table 2: Comparison of clinical and laboratory variables of amayloidosis.
Monsoury et al8 (with 
ASFA)
Wakhlu et al 9 (with 
ASFA)
Gomez-Casanovas et al7 (with 
SFA)
Alishiri et al (with 
ASFB)
No. of patients 112 113 313 220
Positive for amyloid no (%) 8(7) 30(26.5) 51(16%) 15(6.8)
Subclinical amyloid (%) 62.5 73.3 67 46.6
Fat deposit analysis no 8 30 51 15
1+ 7 23 12 13
2+ 1 5 19 2
3+ 0 2 20 0
Duration of disease (year) >5 >5 >5 >5
Age, yrs, mean ± SD 54(41–65) 46 ± 8.7 61.4 ± 13.7 55.2 ± 12
Male: female 0:8 8:22 1:19 1:3
Disease duration, years mean ± SD 17(12–25) 10 ± (5–22) 16.8 ± 10.5 9.13 ± 4.67(5–20)
Age at disease onset, years ± SD 32.5 (22–50) 36 ± 10 44.9 ± 14.4 46.07 (27–65)
Follow up. Mo, mean ± SD - 48 ± 36(12–14) 69.7 ± 53.3 12
RF positive, no. (%) - 25(83.3) 45(75) 10(66.6)
Proteinuria, no (%) 2(25) 7(23.3) 8(13) 8(53.3)
ASFA: Abdominal Subcutaneous Fat Aspiration;
ASFB: Abdominal Subcutaneous Fat Biopsy; 
RF: Rheumatoid Factor.BMC Musculoskeletal Disorders 2006, 7:43 http://www.biomedcentral.com/1471-2474/7/43
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Gómez-Casanovas et al also found the frequency of
marked deposition to be significantly higher in the group
of patients who presented with visceral amyloidosis (57%
vs. 22%) [7].
In our study, 13 of the positive specimens showed mini-
mal and two of them showed moderate amyloid deposi-
tion, but none displayed severe amyloid deposition. Eight
out of 15 patients had clinical amyloidosis, and presented
with proteinuria. No correlation was established between
the intensity of amyloid deposition and the clinical man-
ifestations of the disease. The subjects that tested positive
have been far too few for any definitive conclusions to be
made with regard to the clinical significance of the results.
Significant correlation was suggested between the inten-
sity of the amyloid deposition and the duration of the dis-
ease [3]. In the present study, no significant difference was
found, as related to duration of disease, between the amy-
loid-positive and the amyloid-negative groups.
Although the number of the cases studied is too small to
draw firm conclusions from the results that were
obtained, it suggests constipation and proteinuria to be
prominent features of the study group, which consisted
entirely of Iranian rheumatoid arthritic patients.
A greater number of patients who tested positive for amy-
loid deposition presented with more functional disability
class and progression stage than the ones who tested neg-
ative for amyloid (P < 0.05). No significant difference was
found in laboratory findings between the amyloid-posi-
tive and the amyloid-negative groups, as shown in Table
1.
Conclusion
The study showed that a group of Iranian patients with RA
presented with low prevalence of amyloid deposition
(6.8%); about half of the patients had presented with sub-
clinical disease. Based on the present study and the series
mentioned, it seems that a positive amyloid test result per
se cannot have much clinical significance, especially as
Gómez-Casanovas noted [7,19]. Moreover, a positive test
result for amyloid should not prompt the physician to
adopt a more invasive treatment choice in order to curtail
the progression of the disease. Thus, in our opinion, it
does not stand up to logic that a test with such a low prog-
nostic value as that of the ASFB method be adopted or rec-
ommended as a screen test.
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